INDIAN BENCHMARKS ends higher ahead of February derivative
expiry
INDIAN BENCHMARKS ended a
volatile session of trade in the positive territory ahead of February
derivative contracts expiry tomorrow. This was the third consecutive session of
gains. Cadila
Healthcare is trading higher by 2% extending its yesterday’s nearly 5% rally,
after the company said it has received the final approval from the US FDA to
market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml.
Further, Shares of Ranbaxy Laboratories
was up 2% at Rs369 it has suspended shipments of pharmaceutical ingredients
produced at its Toansa and Dewas plants. Indian Oil Corp is reportedly planning
to buy Malaysian firm Petronas' 10% stake in a shale-gas assets and liquefied-
natural-gas project in British Columbia for $900 mn.
The
crucial resistance for Nifty is now seen at 6300 and above this 6350.
Support for the immediate term is now placed at 6100 and next support
will be 6040.
0 comments:
Post a Comment